Drug updated on 5/17/2024
Dosage Form | Injection (intravenous; 300 mg, 400 mg) |
Drug Class | Monoclonal antibodies |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
- In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Latest News
Summary
- Elotuzumab (Empliciti) is indicated for use in combination with lenalidomide and dexamethasone, or pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received one to three prior therapies, including lenalidomide and a proteasome inhibitor.
- Four systematic reviews/meta-analyses provided an exhaustive analysis of Empliciti's safety and efficacy within the context of multiple myeloma treatment.
- The studies indicate that elotuzumab increases overall survival (OS) by 14% and progression-free survival (PFS) by 20%, particularly when combined with lenalidomide plus dexamethasone or pomalidomide plus dexamethasone.
- Efficacy seems to be especially noted in patients with relapsed/refractory MM, showing a significant reduction in disease progression risk compared to newly diagnosed/untreated MM. However, among various triplet regimens based on pomalidomide and dexamethasone, combinations involving elotuzumab showed lower overall response rates than those containing bortezomib.
- In terms of safety profile, there are concerns about increased risks associated with serious adverse events such as infection or cardiac disorders when using elotuzumab-containing regimens. Another study emphasizes the need for future studies to account for managing these adverse events effectively across monoclonal antibody treatments like this drug class.
- Despite its efficacy benefits over other drugs used for treating multiple myeloma, specifically in increasing OS and PFS rates, careful consideration must be given due to its elevated risk factors.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Empliciti (elotuzumab) Prescribing Information. | 2022 | Bristol-Myers Squibb Company., Princeton, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Safety and efficacy of elotuzumab combination therapy for patients with multiple myeloma: a systematic review and meta-analysis. | 2022 | Expert Review of Anticancer Therapy |
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis. | 2022 | European Review for Medical and Pharmacological Sciences |
A systematic review and network meta-analysis of randomized data on efficacy of novel therapy combinations in patients with lenalidomide-refractory multiple myeloma. | 2021 | Clinical Lymphoma, Myeloma & Leukemia |
Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses. | 2020 | Expert Review of Hematology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. | 2023 | Journal of the NCCN |
Clinical practice guideline multiple myeloma. | 2022 | Myeloma Australia |
Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. | 2021 | Annals of Oncology |
Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. | 2019 | Journal of Clinical Oncology |